Last reviewed 2026-05-14 · How we verify

Eszopiclone 3 mg- Non-elderly

Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.

Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep. Used for Insomnia (sleep initiation and maintenance) in non-elderly adults.

At a glance

Mechanism of action

Eszopiclone is the active S-enantiomer of zopiclone and acts as a positive allosteric modulator of GABA-A receptors, particularly those containing alpha-1 subunits. By enhancing the effect of the inhibitory neurotransmitter GABA, it increases chloride ion influx into neurons, leading to hyperpolarization and reduced neuronal firing. This results in sedation and sleep initiation and maintenance.

Approved indications

• Insomnia (sleep initiation and maintenance) in non-elderly adults

Common side effects

• Headache
• Dizziness
• Somnolence
• Unpleasant taste
• Anxiety
• Dry mouth
• Hallucinations
• Complex sleep behaviors

Key clinical trials

• Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients
• Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients
• A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Eszopiclone 3 mg- Non-elderly CI brief — competitive landscape report
• Eszopiclone 3 mg- Non-elderly updates RSS · CI watch RSS
• Eisai Co., Ltd. portfolio CI